Objectives: Atherosclerosis is a multifactorial disease that correlates positively and significantly
with low-density lipoprotein (LDL) plasma cholesterol and requires inflammatory components.
Whereas reduction of plasma LDL cholesterol is effectively achieved by statins, quenching
of the inflammatory factors has not been addressed adequately by existing therapies.
Resolvins are naturally-occurring, small molecule lipid mediators with the potential
to treat multiple inflammatory diseases. Here we investigated the potency of ω-3 fatty
acid eicosapentaenoic acid derived resolvin E1 (RvE1) in attenuating atherosclerosis
in a humanized mouse model for atherosclerosis, ApoE*3 Leiden transgenic mice
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
EAS-0969
Identification
Copyright
© 2014 Published by Elsevier Inc.
